Addex Therapeutics to Showcase at 13th London International Cough Symposium
On July 12, 2024, Addex Therapeutics ADXN, a clinical-stage biopharmaceutical company specializing in the advancement of novel small molecule allosteric modulators for the treatment of neurological conditions, will make an appearance at the 13th London International Cough Symposium (LICS). The Switzerland-based organization, recognized on the stock market under ADXN at both SIX Swiss Exchange and Nasdaq, stands at the vanguard of developing these cutting-edge therapeutic alternatives. Their efforts are aimed at addressing a variety of complex disorders that affect the central nervous system (CNS).
Industry Presence and Expertise
As an industry leader in the CNS segment, ADXN is known for its innovative approach towards modulating synaptic transmission. This is pivotal in the modulation of complex brain disorders. Dr. Mikhail Kalinichev, Head of Addex Therapeutics, will present the latest findings and progress of the company's research and development. His expertise will offer insights into the direction and future of allosteric modulators in treating neurological disorders.
Peer Performance – Indivior PLC
While biopharmaceutical companies like Addex Therapeutics are making strides in neurological research, peers such as Indivior PLC INDV, are also significant contributors in the pharmaceutical field. Specializing in opioid dependence therapies, the North Chesterfield, Virginia-headquartered INDV has carved a niche in tackling substance abuse and related health conditions with its buprenorphine-based prescription drugs.
Investor Interest in CNS and Addiction Treatments
The R&D advancements by companies like ADXN and INDV underscore an evolving landscape in the treatment of CNS disorders and addiction. These developments often draw significant interest from the investment community, especially considering the potential societal impact and market growth within the pharmaceutical sector. As ADXN presents at the LICS, shareholders and prospective investors will be looking for promising updates that could influence market performance and patient outcomes in the realm of neurological therapeutics.